LEXINGTON, KY / ACCESSWIRE / June 21, 2024 / NX Development Corp. (NXDC) is pleased to announce a significant milestone. Following the FDA’s Orphan Designation for the diagnostic management of ovarian, fallopian tube, and primary peritoneal cancer earlier this year, our first patient was recently enrolled in and successfully completed her surgery with Gleolan as part of our ongoing OVA-302 study.
Salvatore DeSena, MD, CEO of NX Development Corp., responded enthusiastically: “NXDC is thrilled to reach this milestone so quickly in our ovarian development program. Moreover, our second patient has already been scheduled for surgery. Kudos to the NXDC team and our external investigators for these accomplishments!”
Dr. Ulrich Kosciessa, Chairman of the Board of NXDC and CEO of photonamic GmbH & Co KG., adds, “As a group, we are proud to develop Gleolan for fluorescence-guided surgery in oncological diseases. With our OVA-302 study initiated in the US, we aim to expand additional programs into other geographies, e.g., Europe and Japan, and into additional indications in the future. It is exciting to see how fascinated our investigators are about using our technology.”
Gleolan is an optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for visualization of malignant tissue during surgery. It has gained clinical recognition for its use in this regard.
About NX Development Corp:
NX Development Corp., a wholly owned subsidiary of photonamic GmbH & Co. KG, a member of the SBI Holdings Inc. Group (Tokyo, Japan), is dedicated to revolutionizing cancer care through innovative solutions and groundbreaking developments in fluorescence-guided surgery.
For media inquiries, please contact:
Contact Information
Raquel R.
adminpeopledept@nxdevcorp.com
Alicia M.
mediamarketing@nxdevcorp.com
SOURCE: NX Development Corp.
View the original press release on newswire.com.
View the original press release on accesswire.com
AUSTIN, TEXAS / ACCESSWIRE / December 23, 2024 / Interactive Strength Inc. (Nasdaq:TRNR) ("TRNR" or…
Originally published in Quest Diagnostics' 2023 Corporate Responsibility ReportNORTHAMPTON, MA / ACCESSWIRE / December 23,…
Marlborough, Massachusetts--(Newsfile Corp. - December 23, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage…
WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…
WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…
New leadership roles highlight Hallmark’s unique vendor-neutral approach to helping health systems build flexible, efficient,…